Trial results

Does Semaglutide Reduce Alcohol Intake in Patients With Alcohol Use Disorder and Comorbid Obesity?

NCT05895643 on ClinicalTrials.gov · last registry update 2025-08-05

Finished 31 July 2025, after enrolling 108 people. Primary outcome, as filed: Change in heavy drinking days. semaglutide is approved in the US, but not for alcohol use disorder and substance use — a registration here is not an approval, and most drugs tested in a new condition never get one for it.

Status

COMPLETED

Phase

P2

Drug

semaglutide

Wegovy, Ozempic, Rybelsus

Sponsor

Psychiatric Centre Rigshospitalet

Sponsor type

Other

Enrollment

108

Started

2023-06-13

Primary completion

2025-07-31 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Change in heavy drinking days

Conditions studied

Alcohol Abuse · Alcohol Addiction · Alcohol Dependence · Alcohol Use Disorder

Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.